Standard and biological treatment in large vessel vasculitis: guidelines and current approaches

Francesco Muratore, Nicolò Pipitone, Carlo Salvarani

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Introduction: Giant cell arteritis and Takayasu arteritis are the two major forms of idiopathic large vessel vasculitis. High doses of glucocorticoids are effective in inducing remission in both conditions, but relapses and recurrences are common, requiring prolonged glucocorticoid treatment with the risk of the related adverse events. Areas covered: In this article, we will review the standard and biological treatment strategies in large vessel vasculitis, and we will focus on the current approaches to these diseases. Expert commentary: The results of treatment trials with conventional immunosuppressive agents such as methotrexate, azathioprine, mycophenolate mofetil, and cyclophosphamide have overall been disappointing. TNF-α blockers are ineffective in giant cell arteritis, while observational evidence and a phase 2 randomized trial support the use of tocilizumab in relapsing giant cell arteritis. Observational evidence strongly supports the use of anti-TNF-α agents and tocilizumab in Takayasu patients with relapsing disease. However biological agents are not curative, and relapses remain common.

Original languageEnglish
Pages (from-to)345-360
Number of pages16
JournalExpert Review of Clinical Immunology
Volume13
Issue number4
DOIs
Publication statusPublished - Apr 3 2017

Fingerprint

Giant Cell Arteritis
Vasculitis
Guidelines
Recurrence
Glucocorticoids
Mycophenolic Acid
Takayasu Arteritis
Azathioprine
Biological Factors
Immunosuppressive Agents
Methotrexate
Cyclophosphamide
Therapeutics
tocilizumab

Keywords

  • anti-TNF-α
  • biological agents
  • giant cell arteritis
  • immunosuppressive agents
  • Large vessel vasculitis
  • Takayasu arteritis
  • tocilizumab
  • treatment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Standard and biological treatment in large vessel vasculitis : guidelines and current approaches. / Muratore, Francesco; Pipitone, Nicolò; Salvarani, Carlo.

In: Expert Review of Clinical Immunology, Vol. 13, No. 4, 03.04.2017, p. 345-360.

Research output: Contribution to journalReview article

@article{e3c18f58af7b4be68621e2d677f2eaac,
title = "Standard and biological treatment in large vessel vasculitis: guidelines and current approaches",
abstract = "Introduction: Giant cell arteritis and Takayasu arteritis are the two major forms of idiopathic large vessel vasculitis. High doses of glucocorticoids are effective in inducing remission in both conditions, but relapses and recurrences are common, requiring prolonged glucocorticoid treatment with the risk of the related adverse events. Areas covered: In this article, we will review the standard and biological treatment strategies in large vessel vasculitis, and we will focus on the current approaches to these diseases. Expert commentary: The results of treatment trials with conventional immunosuppressive agents such as methotrexate, azathioprine, mycophenolate mofetil, and cyclophosphamide have overall been disappointing. TNF-α blockers are ineffective in giant cell arteritis, while observational evidence and a phase 2 randomized trial support the use of tocilizumab in relapsing giant cell arteritis. Observational evidence strongly supports the use of anti-TNF-α agents and tocilizumab in Takayasu patients with relapsing disease. However biological agents are not curative, and relapses remain common.",
keywords = "anti-TNF-α, biological agents, giant cell arteritis, immunosuppressive agents, Large vessel vasculitis, Takayasu arteritis, tocilizumab, treatment",
author = "Francesco Muratore and Nicol{\`o} Pipitone and Carlo Salvarani",
year = "2017",
month = "4",
day = "3",
doi = "10.1080/1744666X.2017.1285699",
language = "English",
volume = "13",
pages = "345--360",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Standard and biological treatment in large vessel vasculitis

T2 - guidelines and current approaches

AU - Muratore, Francesco

AU - Pipitone, Nicolò

AU - Salvarani, Carlo

PY - 2017/4/3

Y1 - 2017/4/3

N2 - Introduction: Giant cell arteritis and Takayasu arteritis are the two major forms of idiopathic large vessel vasculitis. High doses of glucocorticoids are effective in inducing remission in both conditions, but relapses and recurrences are common, requiring prolonged glucocorticoid treatment with the risk of the related adverse events. Areas covered: In this article, we will review the standard and biological treatment strategies in large vessel vasculitis, and we will focus on the current approaches to these diseases. Expert commentary: The results of treatment trials with conventional immunosuppressive agents such as methotrexate, azathioprine, mycophenolate mofetil, and cyclophosphamide have overall been disappointing. TNF-α blockers are ineffective in giant cell arteritis, while observational evidence and a phase 2 randomized trial support the use of tocilizumab in relapsing giant cell arteritis. Observational evidence strongly supports the use of anti-TNF-α agents and tocilizumab in Takayasu patients with relapsing disease. However biological agents are not curative, and relapses remain common.

AB - Introduction: Giant cell arteritis and Takayasu arteritis are the two major forms of idiopathic large vessel vasculitis. High doses of glucocorticoids are effective in inducing remission in both conditions, but relapses and recurrences are common, requiring prolonged glucocorticoid treatment with the risk of the related adverse events. Areas covered: In this article, we will review the standard and biological treatment strategies in large vessel vasculitis, and we will focus on the current approaches to these diseases. Expert commentary: The results of treatment trials with conventional immunosuppressive agents such as methotrexate, azathioprine, mycophenolate mofetil, and cyclophosphamide have overall been disappointing. TNF-α blockers are ineffective in giant cell arteritis, while observational evidence and a phase 2 randomized trial support the use of tocilizumab in relapsing giant cell arteritis. Observational evidence strongly supports the use of anti-TNF-α agents and tocilizumab in Takayasu patients with relapsing disease. However biological agents are not curative, and relapses remain common.

KW - anti-TNF-α

KW - biological agents

KW - giant cell arteritis

KW - immunosuppressive agents

KW - Large vessel vasculitis

KW - Takayasu arteritis

KW - tocilizumab

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85014941334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014941334&partnerID=8YFLogxK

U2 - 10.1080/1744666X.2017.1285699

DO - 10.1080/1744666X.2017.1285699

M3 - Review article

AN - SCOPUS:85014941334

VL - 13

SP - 345

EP - 360

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 4

ER -